本文已被：浏览 4701次 下载 0次
中文摘要: 目的 观察慢性荨麻疹(Chronic urticaria，CU)患者临床应用枸地氯雷他定的效果及其血清白细胞介素-4（interleukin-4，IL-4)、白细胞介素-18（interleukin-18，IL-18)、白细胞介素-23(interleukin-23，IL-23)和白细胞介素-33(interleukin-33，IL-33)水平表达的影响。方法 选取2015年3月～2016年9月甘肃省武威肿瘤医院收治的CU患者116例作为研究对象，随机分为对照组与研究组，每组各58例。对照组给予氯雷他定片治疗，研究组给予枸地氯雷他定片治疗，两组均持续治疗4周。统计两组治疗前后荨麻疹活动性评分(Urticaria activity score，UAS)及皮肤病生活质量指数(Dermatology Life Quality Index，DLQI)评分，比较两组治疗后临床疗效及治疗中产生的不良反应，检测治疗前后两组血清IL-4、IL-18、IL-23和IL-33水平。结果 治疗后两组UAS、DLQI评分和血清指标均得到明显的降低，且研究组结果优于对照组(P＜0.05)；治疗后研究组、对照组总有效率分别为84.48%、58.62%，差异显著(P＜0.05)，两组患者在不良反应发生率方面无明显差异(P＞0.05)；结论 CU患者临床应用枸地氯雷他定治疗效果显著，可改善其血清IL-4、IL-18、IL-23和IL-33表达水平。
Abstract:Objective To investigate the curative effect of Desloratadine Citrate Disodium in patients with chronic urticaria(CU) and its influence on serum interleukin-4(IL-4),interleukin-18(IL-18),interleukin-23(IL-23)andinterleukin-33(IL-33) levels. Methods 116 CU patients in our hospital from March 2015 to September 2016 were randomly divided into two groups: control group and study group，each with 58 cases. The control group was given Loratadine treatment, while the study group was given Desloratadine Citrate Disodium treatment, and the 2 groups treatments were continued for 4 weeks. The urticaria activity score (UAS) and Dermatology Life Quality Index (DLQI) score of the 2 groups before and after treatments were counted, curative effects after treatment and adverse reactions during treatment of the 2 groups were compared, and serum IL-4, IL-18, IL-23 and IL-33 levels of the 2 groups before and after treatments were detected. Results After treatment, the UAS and DLQI scores of the 2 groups were significantly lower than before(P＜0.05), and the study group were significantly lower than that of the control group(P＜0.05); After treatment, the total effective rate of the study was 84.48%, significantly higher than that of the control group 58.62%(P＜0.05), and there was no significant difference in the incidence of adverse reactions between the 2 groups (P＞0.05);
After treatment, serum IL-4, IL-18, IL-23 and IL-33 levels of the 2 groups were significantly lower than before (P＜0.05), and the study group was significantly lower than that of the control group(P＜0.05). CONCLUSION Desloratadine Citrate Disodium for patients with CU can significantly increase curative effect, improve their serum IL-4, IL-18, IL-23 and IL-33 levels.
keywords: chronic urticaria Desloratadine Citrate Disodium interleukin-4 interleukin-18 interleukin-23 interleukin-33
文章编号：3201807029 中图分类号：R758.24 文献标志码：
基金项目:
| 作者 | 单位 |
| 徐延峰① |
| Author Name | Affiliation |
引用文本：